GenomeDx's Decipher GRID and Decipher Tests to be Featured in Multiple Abstracts at the 111th American Urological Association Annual Meeting

SAN DIEGO, April 28, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that eight abstracts featuring Decipher Genomics Resource Information Database (Decipher GRID^®) and Decipher^® Tests in Prostate and Bladder Cancer will be presented at the American Urological Association (AUA) 2016 Annual Meeting held May 6-10 in San Diego. The AUA meeting is the largest gathering of urologists in the world, showcasing the latest advances in urologic medicine and offering unparalleled access to groundbreaking research.

Presentations:
Friday, May 6
Title: Evaluation of a Genomic Classifier in Radical Prostatectomy Patients with Lymph Node Metastasis
Poster Session: Prostate Cancer: Markers I - Room 31 (8:00 a.m. to 10:00 a.m. PDT)
Poster Number: MP02-06
Presenter: Dr. Christopher Kane, University of California, San Diego

Title: Validation of a Genomic Risk Classifier to Predict Prostate Cancer Death in High Risk Patients
Poster Session: Prostate Cancer: Markers II - Room 28ABC (10:30 a.m. to 12:30 p.m. PDT)
Poster Number: MP07-01
Presenter: Dr. Bruce Trock, Johns Hopkins University

Title: Primary Tumor Androgen Receptor Signaling as a Predictor of Castrate Resistance
Poster Session: Prostate Cancer: Markers II - Room 28ABC (10:30 a.m. to 12:30 p.m. PDT)
Poster Number: MP07-03
Presenter: Dr. Ashley Ross, Johns Hopkins University

Title: Predicting Adverse Pathological Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy (RP): The Role of Genomic Signatures
Poster Session: Prostate Cancer: Markers II - Room 28ABC (10:30 a.m. to 12:30 p.m. PDT)
Poster Number: MP07-07
Presenter: Dr. Firas Abdollah, Vattikuti Urology Institute - Henry Ford Hospital

Title: The Frequency of Druggable Targets in Localized Prostate Cancer: Initial Analysis from the Decipher GRID
Poster Session: Prostate Cancer: Markers II - Room 28ABC (10:30 a.m. to 12:30 p.m. PDT)
Poster Number: MP07-10
Presenter: Dr. Elai Davicioni, GenomeDx

Title: Development and Validation of Genomic Signature that Predicts ADT Treatment Failure
Poster Session: Prostate Cancer: Markers II - Room 28ABC (10:30 a.m. to 12:30 p.m. PDT)
Poster Number: MP07-20
Presenter: Dr. R. Jeffrey Karnes, Mayo Clinic

Title: Efficacy of Early and Delayed Radiation in a Prostatectomy Cohort Adjusted for Genomic and Clinical Risk
Poster Session: Prostate Cancer: Localized: Radiation Therapy - Room 25 (1:00 p.m. to 3:00 p.m. PDT)
Poster Number: MP14-12
Presenter: Dr. Ashley Ross, Johns Hopkins University

Sunday, May 8
Title: Neoadjuvant Chemotherapy in Bladder Cancer: p53-ness is Associated with Chemo-Resistance and Unfavorable Outcome
Podium Session: Bladder Cancer: Invasive IV - Room 29AB (3:30 p.m. to 5:30 p.m. PDT)
Podium Number: PD33-11
Presenter: Dr. Roland Seiler, University of British Columbia - Vancouver

About Decipher® Prostate Cancer Classifier Tests
Our Decipher prostate cancer classifier tests are currently comprised of Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient's unique genomic profile. Decipher Biopsy is indicated for men after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.

Learn more at www.DecipherTest.com

About Decipher GRID^®
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic data sharing platform that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patients, and constitutes what we believe to be the world's largest shared, clinically-annotated genomic expression database in urologic oncology and one of the world's largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables more rapid discovery, development, commercialization and adoption of existing and new products. Through Decipher GRID, GenomeDx is building a suite of genomic tests to assist physicians and patients with clinical decision-making from disease screening through late-stage therapy.    

Learn more at www.DecipherGRID.com

About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic oncology that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is based in Vancouver, British Columbia and San Diego, California.

Learn more at www.GenomeDx.com

Media Contact:
Ian Stone
Canale Communications
619-849-5388
[email protected]

SOURCE GenomeDx Biosciences

Related Links

http://www.genomedx.com